Autres langues Incyte Corporation

Actions

INCY

US45337C1027

Produits pharmaceutiques

Temps réel estimé Cboe BZX Autres places de cotation 20:36:12 16/06/2026			Varia. 5j.	Varia. 1 janv.
99,56 ^USD	-2,37 %		-3,32 %	+1,04 %

15/06	Mirum Pharmaceuticals et Incyte annoncent une réduction significative des lésions d'ossification hétérotopique grâce au zilurgisertib lors d'un essai clinique	MT
14/06	Mirum Pharmaceuticals et Incyte annoncent des résultats pivots positifs de phase 2 pour l'étude PROGRESS sur le zilurgisertib dans la fibrodysplasie ossifiante progressive	CI

Autres langues

15/06	Incyte gibt auf der EHA 2026 neue positive Daten bekannt, wonach INCA033989 bei Patienten mit Myelofibrose und essenzieller Thrombozythämie schnelle, robuste und anhaltende klinische und molekulare Reaktionen erzielte und gut vertragen wurde
15/06	Ergebnisse der zulassungsrelevanten Phase-3-Studie „frontMIND“ von Incyte zur Kombination von Tafasitamab (Monjuvi® /Minjuvi® ), die auf der Plenarsitzung des Kongresses der European Hematology Association (EHA) 2026 vorgestellt wurden...
15/06	Mirum Pharmaceuticals, Incyte Say Zilurgisertib Showed Meaningful Reductions in Heterotopic Ossification Lesion Volume During Clinical Trial
14/06	Incyte : Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
14/06	Mirum Pharmaceuticals, Inc. and Incyte Report Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
13/06	Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia
13/06	Incyte Announces Updated Clinical Data From Two Phase 1 Studies Evaluating INCA033989 In Patients With MutCALR-Expressing Myeloproliferative Neoplasms
13/06	Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival
13/06	Incyte Presents Results from Pivotal Phase 3 Frontmind Trial of Tafasitamab Combination At Eha 2026 Plenary
11/06	Analyst recommendations: Chewy, CME Group, Ford Motor, Fortinet, Humana…
08/06	Health Care Ticks Down Amid Deal Activity - Health Care Roundup
08/06	Incyte Insider Sold Shares Worth $263,900, According to a Recent SEC Filing
08/06	Incyte To Acquire Vega Therapeutics For Up To $2 Billion
08/06	Incyte Corporation entered into a definitive agreement to acquire to acquire Vega Therapeutics, Inc. from Star Therapeutics, Inc. for $2 billion.
08/06	Incyte to Acquire Star Therapeutics unit Vega; Shares Up Pre-Bell
08/06	Incyte makes $2 billion bet on bleeding disorder drug ahead of Jakafi patent cliff
08/06	Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
08/06	PRESSESPIEGEL/Unternehmen
07/06	Incyte nears up to $2 billion deal for blood disorder biotech Star, FT reports
04/06	Incyte, Mirum Pharmaceuticals to Present New Zilurgisertib Study Results at Conference
01/06	Die zulassungsrelevante frontMIND-Studie von Incyte zeigte, dass die Kombination mit Tafasitamab (Monjuvi®/Minjuvi®) das progressionsfreie Überleben signifikant verlängerte und das Risiko eines Krankheitsfortschritts oder des Todes bei Patienten...
01/06	Wall Street comienza junio en tensión
01/06	Wall Street startet nervös in den Juni
01/06	Wall Street Starts June on Edge
30/05	Incyte says Frontmind trial shows 25% reduction in disease progression or death in high-risk DLBCL